Abstract
Alzheimers disease (AD) is characterized by two major features: (1) degeneration of basal forebrain cholinergic neurons and ensuing deficient cholinergic functions in cortex and hippocampus; (2) extracellular protein aggregates containing β-amyloid peptides (Aβ) in these cholinergic target areas. So far, the most effective therapy for AD is to enhance cholinergic transmission. Neuromodulatory functions of the cholinergic system are mainly mediated by muscarinic receptors (mAChRs). It has long been recognized that mAChRs are crucial for the control of high-level cognitive processes. Drugs that activate mAChRs are helpful in ameliorating cognitive deficits of AD. On the other hand, mounting evidence have established detrimental effects of Aβ to cognitive functions. Despite intensive research on AD, it remains unclear how these two prominent features of the disease may be linked to cause cognitive impairments. In this review, we will summarize a series of recent findings on the interactions between cholinergic functions and β-amyloid in normal animals and AD models, and discuss their potential implications in the pathophysiology and treatment of Alzheimers disease.
Keywords: alzheimers disease, cholinergic, muscarinic receptors, amyloid peptides, insulin, gabaergic transmission, prefrontal cortex, protein kinase c
Current Alzheimer Research
Title: Alzheimers Disease: Interactions Between Cholinergic Functions and β- amyloid
Volume: 1 Issue: 4
Author(s): Zhen Yan and Jian Feng
Affiliation:
Keywords: alzheimers disease, cholinergic, muscarinic receptors, amyloid peptides, insulin, gabaergic transmission, prefrontal cortex, protein kinase c
Abstract: Alzheimers disease (AD) is characterized by two major features: (1) degeneration of basal forebrain cholinergic neurons and ensuing deficient cholinergic functions in cortex and hippocampus; (2) extracellular protein aggregates containing β-amyloid peptides (Aβ) in these cholinergic target areas. So far, the most effective therapy for AD is to enhance cholinergic transmission. Neuromodulatory functions of the cholinergic system are mainly mediated by muscarinic receptors (mAChRs). It has long been recognized that mAChRs are crucial for the control of high-level cognitive processes. Drugs that activate mAChRs are helpful in ameliorating cognitive deficits of AD. On the other hand, mounting evidence have established detrimental effects of Aβ to cognitive functions. Despite intensive research on AD, it remains unclear how these two prominent features of the disease may be linked to cause cognitive impairments. In this review, we will summarize a series of recent findings on the interactions between cholinergic functions and β-amyloid in normal animals and AD models, and discuss their potential implications in the pathophysiology and treatment of Alzheimers disease.
Export Options
About this article
Cite this article as:
Yan Zhen and Feng Jian, Alzheimers Disease: Interactions Between Cholinergic Functions and β- amyloid, Current Alzheimer Research 2004; 1 (4) . https://dx.doi.org/10.2174/1567205043331992
DOI https://dx.doi.org/10.2174/1567205043331992 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
In Vitro Regulatory Effect of Epididymal Serpin CRES on Protease Activity of Proprotein Convertase PC4/PCSK4
Current Molecular Medicine Bioinformatics Approach to BDNF and BDNF-Related Disorders
Current Neuropharmacology Lipid-Based Drug Delivery Systems for Cancer Treatment
Current Drug Targets Immunomodulatory Properties of Antibiotics
Current Molecular Pharmacology Novel Insights into Targeting ATP-Binding Cassette Transporters for Antitumor Therapy
Current Medicinal Chemistry Emerging Synergisms Between Drugs and Physiologically-Patterned Weak Magnetic Fields: Implications for Neuropharmacology and the Human Population in the Twenty-First Century
Current Neuropharmacology The Role of the Anti-Amyloidogenic Secretase ADAM10 in Shedding the APP-like Proteins
Current Alzheimer Research A Proteomic Analysis of Mitochondrial Complex III Inhibition in SH-SY5Y Human Neuroblastoma Cell Line
Current Proteomics Intracellular Accumulation of Toxic Turn Amyloid-β is Associated with Endoplasmic Reticulum Stress in Alzheimer’s Disease
Current Alzheimer Research Curcumin, Resveratrol and Cannabidiol as Natural Key Prototypes in Drug Design for Neuroprotective Agents
Current Neuropharmacology Supplementation with Curcuma longa Reverses Neurotoxic and Behavioral Damage in Models of Alzheimer’s Disease: A Systematic Review
Current Neuropharmacology Neuroprotective Role of Natural Polyphenols
Current Topics in Medicinal Chemistry Atypical GTPases as Drug Targets
Anti-Cancer Agents in Medicinal Chemistry Interleukin-15 in Gene Therapy of Cancer
Current Gene Therapy HER2 in the Era of Molecular Medicine: A Review
Current Cancer Therapy Reviews Leukocyte P2 Receptors: A Novel Target for Anti-inflammatory and Antitumor Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Hematopoietic Stem Cells Therapies
Current Stem Cell Research & Therapy The Effect of Lipoic Acid on Macro and Trace Metal Levels in Living Tissues Exposed to Oxidative Stress
Anti-Cancer Agents in Medicinal Chemistry Is alpha-Synuclein Pathology a Target for Treatment of Neurodegenerative Disorders?
Current Alzheimer Research Oxidative Stress and Amyloid Beta Toxicity in Alzheimer’s Disease: Intervention in a Complex Relationship by Antioxidants
Current Medicinal Chemistry